Integrated Prospective Analysis of Radiomic and Immunologic Signatures in Nasopharyngeal Carcinoma Treated With Proton or Photon Radiotherapy
To prospectively investigate and integrate radiomic and immunologic signatures in patients with nasopharyngeal carcinoma (NPC) treated with either proton or photon radiotherapy, with the aim of identifying biomarkers associated with treatment response, toxicity, and long-term outcomes.
• Willingness to provide written informed consent.
• Pathologically confirmed diagnosis of nasopharyngeal carcinoma
• Age ≥18 years
• ECOG performance status 0-1
• Patients with AJCC v.9 stage I-III disease who undergo chemoradiotherapy
• Adequate bone marrow, liver, and renal function within 4 weeks before study registration
‣ Hemoglobin ≥ 9.0 g/dL
⁃ Absolute neutrophil count (ANC) ≥ 1,000/mm3
⁃ Platelet count ≥ 50,000/μL
⁃ Total bilirubin \< 2.5 mg/dL
⁃ Serum albumin \>2.8 g/dL
⁃ Serum creatinine ≤ 1.5 mg/dL